Whole Virion(整个病毒体)研究综述
Whole Virion 整个病毒体 - A variety of diagnostic techniques, including chest X-rays, computer tomography (CT) scans, analysis of viral nucleic acids, proteins, or whole virions, and host antibody detection using serological assays have been developed for the detection of these viruses. [1] 5 × 107 clones taken from a naïve yeast surface-displayed human fibronectin domain (Fn3) against whole virions yielded two unique binders to Zika virions. [2] We postulated that an important contributor to this outcome is the poor processability of whole virions for MHC-II–restricted presentation. [3] HydroVax-001 WNV is a hydrogen peroxide inactivated, whole virion (WNV-Kunjin strain) vaccine adjuvanted with aluminum hydroxide. [4] The use of plants for the production of virus-like nanoparticles (VNPs) dates back to separating natural empty capsids of plant viruses from whole virions nearly 70 years ago, through to the present use of transgenic plants or recombinant Agrobacterium tumefaciens and/or plant virus-derived vectors for the transient expression of engineered viral or other structural proteins in plants-a production system also known as molecular farming. [5] IgG binding to whole gB, gB-neutralizing epitopes, FCRs, and whole virions were assessed by standard or multiplex ELISA. [6] Current commercial vaccines contain the first-identified PCV2a’s capsid protein or whole virions. [7] All of the sera were capable of binding gD, gB, and whole virions, and all sera significantly neutralized cell-free virus. [8] We used hemagglutination inhibition assay to assess the immunogenicity of a newly developed, whole virion, seasonal trivalent influenza vaccine, containing 6 µg hemagglutinin per strain (FluArt, Hungary) and to assess whether it is non-inferior to the presently licensed vaccine containing 15 µg hemagglutinin per strain. [9]已经开发了多种诊断技术，包括胸部 X 射线、计算机断层扫描 (CT) 扫描、病毒核酸、蛋白质或整个病毒体的分析，以及使用血清学测定法检测宿主抗体来检测这些病毒。 [1] 5 × 107 个克隆取自幼稚酵母表面展示的人纤连蛋白结构域 (Fn3)，针对整个病毒体产生了两种独特的寨卡病毒体结合剂。 [2] 我们假设这一结果的一个重要因素是整个病毒粒子对 MHC-II 限制性呈递的可加工性差。 [3] HydroVax-001 WNV 是一种以氢氧化铝为佐剂的过氧化氢灭活全病毒粒子（WNV-Kunjin 株）疫苗。 [4] 使用植物生产病毒样纳米颗粒 (VNP) 可以追溯到近 70 年前将植物病毒的天然空衣壳与整个病毒体分离，直至目前使用转基因植物或重组的根癌农杆菌和/或植物病毒- 用于在植物中瞬时表达工程病毒或其他结构蛋白的衍生载体 - 一种生产系统，也称为分子农业。 [5] 通过标准或多重ELISA评估IgG与全gB、gB中和表位、FCR和全病毒粒子的结合。 [6] 目前的商业疫苗含有首次鉴定的 PCV2a 的衣壳蛋白或整个病毒体。 [7] 所有血清都能够结合gD、gB和整个病毒体，并且所有血清都显着中和了无细胞病毒。 [8] 我们使用血凝抑制试验来评估新开发的全病毒体季节性三价流感疫苗的免疫原性，每株含 6 µg 血凝素（FluArt，匈牙利），并评估它是否不劣于目前许可的含 15 µg 的疫苗每株血凝素。 [9]
Inactivated Whole Virion 灭活的整个病毒粒子
Porcine Circovirus 2 (PCV2) vaccines are based on either inactivated whole virion, or recombinant ORF2 capsid protein assembled into Virus-like Particles (VLPs). [1] Methods Two-dose (14 days apart) vaccination regimen with formalin-inactivated whole virion SARS-CoV-2 in golden Syrian hamster model was established. [2] Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. [3] Immunization program against COVID-19 in India started with two vaccines; AstraZeneca ChAdOx1-nCov-19 (termed Covishield in India) and inactivated whole virion BBV152 (Covaxin); homologous prime-boost approach was followed. [4] Here, we developed a β-propiolactone-inactivated whole virion vaccine CoviVac and assessed its safety, protective efficacy, immunogenicity and stability of the immune response in rodents and non-human primates. [5] Porcine Circovirus 2 (PCV2) vaccines are based on either inactivated whole virion, or recombinant ORF2 capsid protein assembled into Virus-like Particles (VLPs). [6]猪圆环病毒 2 (PCV2) 疫苗基于灭活的完整病毒体或组装成病毒样颗粒 (VLP) 的重组 ORF2 衣壳蛋白。 [1] 方法在金叙利亚仓鼠模型中建立福尔马林灭活全病毒颗粒SARS-CoV-2两剂（间隔14天）疫苗接种方案。 [2] 在这里，我们研究了 18 名参与者，他们接受了阿斯利康的 ChAdOx1-nCov-19 异源疫苗接种方案，然后是灭活的全病毒粒子 BBV152。 [3] 印度针对 COVID-19 的免疫计划从两种疫苗开始； AstraZeneca ChAdOx1-nCov-19（在印度称为 Covishield）和灭活的全病毒粒子 BBV152（Covaxin）；采用同源初始-增强方法。 [4] 在这里，我们开发了一种 β-丙内酯灭活的全病毒粒子疫苗 CoviVac，并评估了其在啮齿动物和非人类灵长类动物中的安全性、保护效力、免疫原性和免疫反应的稳定性。 [5] 猪圆环病毒 2 (PCV2) 疫苗基于灭活的完整病毒体或组装成病毒样颗粒 (VLP) 的重组 ORF2 衣壳蛋白。 [6]
whole virion inactivated 整个病毒粒子灭活
A 27-year-old man developed multiple itchy reddish, elevated lesions following one after the second dose of COVID-19 vaccine (whole virion inactivated coronavirus vaccine). [1] We report the development and evaluation of safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminium hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel. [2] These cohorts received either ChAdOx nCOV-19 (Recombinant) or the whole virion inactivated Vero cell vaccines. [3] With the advent of SARSCoV2 vaccines viz, mRNA, recombinant adenovirus vector and whole virion inactivated vero cell, which are inactivated vaccines having emergency use authorisation granted by the US Food and Drug Administration on 11 December 2020, led to a ray of hope in the COVID19 pandemic. [4] Subsequently, a whole virion inactivated candidate vaccine, QazCovid-in, was developed based on this virus. [5] Covaxin/BBV152 is a whole virion inactivated SARS-CoV-2 vaccine. [6] Background: We report the clinical efficacy against COVID 19 infection of BBV152, a whole virion inactivated SARS CoV 2 vaccine formulated with a Toll like receptor 7/8 agonist molecule adsorbed to alum (Algel IMDG). [7] Subsequently, a whole virion inactivated candidate vaccine, QazCovid-in, was developed based on this virus. [8] PVI was investigated after recombinant ChAdOx nCOV-19 (Recombinant) or the whole virion inactivated Vero cell vaccines were administered. [9]一名 27 岁男子在第二剂 COVID-19 疫苗（全病毒粒子灭活冠状病毒疫苗）后出现多处发痒、微红色、隆起的病变。 [1] 我们报告了以氢氧化铝凝胶 (Algel) 或 TLR7/8 激动剂化学吸附 Algel 为佐剂的全病毒粒子灭活 (WVI) SARS-CoV-2 疫苗 (BBV152) 的安全性和免疫原性的开发和评估。 [2] 这些队列接受了 ChAdOx nCOV-19（重组）或全病毒粒子灭活的 Vero 细胞疫苗。 [3] 随着 SARSCoV2 疫苗的问世，即 mRNA、重组腺病毒载体和全病毒粒子灭活维罗细胞，这些灭活疫苗已于 2020 年 12 月 11 日获得美国食品和药物管理局的紧急使用授权，为 COVID19 带来了一线希望大流行。 [4] 随后，基于该病毒研发了一种全病毒粒子灭活候选疫苗QazCovid-in。 [5] Covaxin/BBV152 是一种全病毒粒子灭活的 SARS-CoV-2 疫苗。 [6] 背景：我们报告了 BBV152 对 COVID 19 感染的临床疗效，BBV152 是一种全病毒粒子灭活的 SARS CoV 2 疫苗，由吸附在明矾上的 Toll 样受体 7/8 激动剂分子 (Algel IMDG) 配制而成。 [7] 随后，基于该病毒研发了一种全病毒粒子灭活候选疫苗QazCovid-in。 [8] 在施用重组 ChAdOx nCOV-19（重组）或全病毒粒子灭活 Vero 细胞疫苗后研究 PVI。 [9]
whole virion vaccine 全病毒粒子疫苗
It is possible that whole virion vaccines (CoviVac) have an advantage over others when vaccinating solid organ recipients, but clinical experience in this matter has not yet been obtained. [1] We have recently shown that using a whole virion vaccine with aluminum phosphate adjuvants, reduced dose vaccines containing 6 µg of viral hemagglutinin (HA) per strain are immunogenic, and well tolerated in adult and elderly patients. [2] Here, we developed a β-propiolactone-inactivated whole virion vaccine CoviVac and assessed its safety, protective efficacy, immunogenicity and stability of the immune response in rodents and non-human primates. [3] Furthermore, the results of this preliminary evaluation suggest that preparation of a whole virion vaccine for COVID-19 using this specific photochemical method may have potential utility in the preparation of one such vaccine candidate. [4]在为实体器官受体接种疫苗时，全病毒粒子疫苗 (CoviVac) 可能比其他疫苗具有优势，但尚未获得这方面的临床经验。 [1] 我们最近表明，使用带有磷酸铝佐剂的全病毒粒子疫苗，每株含有 6 µg 病毒血凝素 (HA) 的减量疫苗具有免疫原性，并且在成人和老年患者中具有良好的耐受性。 [2] 在这里，我们开发了一种 β-丙内酯灭活的全病毒粒子疫苗 CoviVac，并评估了其在啮齿动物和非人类灵长类动物中的安全性、保护效力、免疫原性和免疫反应的稳定性。 [3] 此外，该初步评估的结果表明，使用这种特定的光化学方法制备 COVID-19 的完整病毒粒子疫苗可能在制备一种此类候选疫苗中具有潜在用途。 [4]
whole virion bbv152 整个病毒体 Bbv152
Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. [1] Immunization program against COVID-19 in India started with two vaccines; AstraZeneca ChAdOx1-nCov-19 (termed Covishield in India) and inactivated whole virion BBV152 (Covaxin); homologous prime-boost approach was followed. [2]在这里，我们研究了 18 名参与者，他们接受了阿斯利康的 ChAdOx1-nCov-19 异源疫苗接种方案，然后是灭活的全病毒粒子 BBV152。 [1] 印度针对 COVID-19 的免疫计划从两种疫苗开始； AstraZeneca ChAdOx1-nCov-19（在印度称为 Covishield）和灭活的全病毒粒子 BBV152（Covaxin）；采用同源初始-增强方法。 [2]